Professional
Added to YB: 2026-01-05
Pitch date: 2025-12-31
ACHV [bullish]
Achieve Life Sciences, Inc.
+4.22%
current return
Author Info
Hunterbrook Media publishes investigative and global reporting with no ads or paywalls. Their mission is to bring visibility to under-covered regions and accountability to under-scrutinized sectors. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$264.6M
Pitch Price
$4.98
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.35
P/E
-3.68
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Put it in the water!” — How a Toxic Tree May Save Thousands of Smokers
ACHV: $250M biotech seeking FDA approval (June 20, 2026) for cytisinicline, smoking cessation therapy outperforming Chantix with fewer side effects. Phase 3 trials: 32.6% vs 7% placebo quit rates. Also targeting first vaping cessation drug (breakthrough designation). ACA mandates smoking cessation coverage. $48M cash (~9mo burn). Bulls: massive market, proven efficacy. Bears: financing needs for commercialization.
Read full article (18 min)